Jonathan Trent, MD, PhD, University of Miami, Miami, FL, discusses findings from a multi-omics study of gastrointestinal stromal tumor (GIST) in a real-world patient cohort. NF1 and NTRK3 mutations were identified in patients with wild-type GIST. However, KIT/PDGFRA mutations such as KIT exon 11 mutations were associated with poorer outcomes. These findings suggest that immunotherapies such as immune checkpoint inhibitors may be efficacious in these patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть